InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 [Yahoo! Finance]
InflaRx N.V. (IFRX)
Last inflarx n.v. earnings: 8/14 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
inflarx.com/home/investors/press-releases/01-2018--inflarx-to-present-at-upcoming-investor-conferences.html
Company Research
Source: Yahoo! Finance
InflaRx believes that CSU and HS each have potential addressable markets of 1 billion or more for INF904. The company also believes that INF904 could address meaningful opportunities in additional immuno-dermatology and immuno-inflammatory indications, including in nephrology, neurology, and hematology. Was this helpful? Yes No What is the current development stage of InflaRx's oral C5aR inhibitor, INF904, and what is the purpose of the Phase 2a study? The first patient has been dosed in the Phase 2a basket study of INF904, which aims to investigate the safety and efficacy of the treatment in patients with chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS). The study will evaluate multiple dosing regimens over 4 weeks to generate additional safety and pharmacokinetic data and provide signs of clinical benefit. Was this helpful? Yes No What are the characteristics of INF904, and what are the results of previous studies on the treatment? INF904 is
Show less
Read more
Impact Snapshot
Event Time:
IFRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IFRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IFRX alerts
High impacting InflaRx N.V. news events
Weekly update
A roundup of the hottest topics
IFRX
News
- InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904GlobeNewswire
- InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome [Yahoo! Finance]Yahoo! Finance
- InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress SyndromeGlobeNewswire
- InflaRx Reports Q3 2024 Financial Results and Progress [Yahoo! Finance]Yahoo! Finance
IFRX
Earnings
- 11/8/24 - Miss
IFRX
Sec Filings
- 12/20/24 - Form 6-K
- 11/15/24 - Form 6-K
- 11/8/24 - Form 6-K
- IFRX's page on the SEC website